Regenxbio

Regenxbio

Yahoo Finance • 26 days ago

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

REGENXBIO RGNX stock plunged 24.9% on Monday after the FDA placed a clinical hold on its investigational one-time gene therapy, RGX-121, for the treatment of boys with Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome.... Full story

Yahoo Finance • 27 days ago

Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling

Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company’s investigational therapy for Hunter syndome. Continue Reading... Full story

Yahoo Finance • last month

Street Calls of the Week

Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week. InvestingPro subscribers always get first dibs on market-moving AI analyst comments. Upgrade today! Fair Isaac Corp. What's the fu... Full story

Yahoo Finance • last month

Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended into Q4 2027 on ...

This article first appeared on GuruFocus. Cash Position: Ended Q2 2026 with cash, equivalents, and marketable securities of $106 million. Pro Forma Cash: More than $310 million after receiving a $100 million milestone payment from AbbVie... Full story

Yahoo Finance • last month

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data highlight durable safety and efficacy prof... Full story

Yahoo Finance • 2 months ago

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies: Stable to improved vision through 5 years in wet AMD patients who required frequent ant... Full story

Yahoo Finance • 2 months ago

REGENXBIO Prices $100M Public Offering To Advance Gene Therapy Programs; Stock Down

(RTTNews) - Shares of REGENXBIO Inc. (RGNX) fell nearly 20% after the company announced it has priced a $100 million public offering of common stock and pre-funded warrants. The offering includes 10,003,889 shares of common stock at $9.00... Full story

Yahoo Finance • 2 months ago

Netflix, Intuitive Surgical tumble premarket

Investing.com - U.S. stock index futures fell sharply on Friday, pointing to a second straight day of losses on Wall Street as investors continued to reassess lofty technology valuations following a string of disappointing corporate update... Full story

Yahoo Finance • 2 months ago

REGENXBIO stock dips on $100M equity offering

* REGENXBIO (RGNX [https://seekingalpha.com/symbol/RGNX]) priced an underwritten public offering of about 10M common shares at $9.00 each and 1.11M pre-funded warrants at $8.9999 apiece, with expected gross proceeds of approximately $100... Full story

Yahoo Finance • 2 months ago

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) breached their fiduciary duties to shareholders. A... Full story

Yahoo Finance • 3 months ago

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

New long-term data from diabetic retinopathy and wet AMD programs to be presented atAmerican Society of Retina Specialists (ASRS) 2026 ROCKVILLE, Md., June 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the first p... Full story

Yahoo Finance • 3 months ago

AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers

On this episode of Stock Movers with Nathan Hager:- Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Finan... Full story

Yahoo Finance • 3 months ago

Pre-Market Movers: TNON, ADTX, LNAI See Sharp Moves

(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Pre-market movers give traders an early read on momentum, sentiment, and potential volatility for the trading day. Price swings before the opening bell... Full story

Yahoo Finance • 3 months ago

Wednesday Sector Leaders: Computers, Biotechnology Stocks

In trading on Wednesday, computers shares were relative leaders, up on the day by about 5.6%. Leading the group were shares of AstroNova, up about 70.2% and shares of Nano Dimension Ltd (NNDM) up about 9.8% on the day. Also showing relat... Full story

Yahoo Finance • 4 months ago

Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway

Regenxbio Inc (NASDAQ:RGNX) is one of the best gene therapy stocks to buy in 2026. On May 14, Regenxbio reported its Q1 2026 financial results and provided operational updates. The company exited the quarter with $150.5 million in cash. Th... Full story

Yahoo Finance • 4 months ago

Regenxbio Shares Rise After Positive Duchenne Trial Results

medical research 10 ©Pixnio Regenxbio (NASDAQ:RGNX) shares gained more than 4% in premarket trading Thursday after investors focused on encouraging clinical trial results for the company’s Duchenne muscular dystrophy therapy, despite weak... Full story

Yahoo Finance • 4 months ago

Regenxbio slides after late-stage trial data for Duchenne therapy

[Duchenne muscular dystrophy genetic test] Hailshadow/iStock via Getty Images Following a brief trading halt, Regenxbio (RGNX [https://seekingalpha.com/symbol/RGNX]) lost ~18% in the premarket on Thursday after the company, alongside its... Full story

Yahoo Finance • 4 months ago

REGENXBIO Reports Positive Topline Data From Phase III AFFINITY DUCHENNE Trial Of RGX-202

(RTTNews) - REGENXBIO Inc. (RGNX) on Thursday announced positive topline and interim functional data from the pivotal Phase III AFFINITY DUCHENNE trial of RGX-202, the company's gene therapy candidate for Duchenne Muscular Dystrophy. The... Full story

Yahoo Finance • 5 months ago

Levi & Korsinsky, LLP: RGNX Disclosure Timeline Reveals Pattern of Alleged Investor Harm

NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP encourages investors who suffered losses in REGENXBIO, Inc. (NASDAQ: RGNX) to contact the firm. Those who purchased RGNX securities between February 9, 2022 and January 2... Full story

Yahoo Finance • 5 months ago

REGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - RGNX

NEW YORK, April 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class... Full story